DE-BIOCORP
1.10.2020 07:32:15 CEST | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the design, development and manufacture of innovative medical devices, today announced an alliance with Belgium-based AARDEX Group, the world leader in medication adherence solutions.
This alliance is to combine BIOCORP’s connected add-on solutions for drug delivery devices with AARDEX’s proprietary Medication Event Monitoring System (MEMS®) and offer a comprehensive solution to patients and healthcare providers to effectively measure and manage medication adherence. The financial terms of the agreement have not been disclosed, however the first initiative will be to integrate BIOCORP’s Injay connected solution for Pre-filled syringes (PFS) to AARDEX’s MEMS Adherence Software (MEMS AS® ), to target medicines delivered by PFS with potential applications in the field of Rheumatoid Arthritis, Multiple Sclerosis, Ophthalmology, Psoriasis or Cardiovascular diseases. The roadmap also includes integration with BIOCORP’s other connected devices, to cover further chronic conditions in the field of injectable, respiratory, and beyond.
David Dalla Vecchia, CEO and Financial Lead of AARDEX Group, said: "We are delighted to announce our partnership with BIOCORP. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment. Partnering with BIOCORP - a true pioneer in connected devices - will significantly contribute to that objective and bring together a wealth of knowledge and experience to help meet the needs of today’s clinical trials, patients and healthcare providers.”
Éric Dessertenne, CEO of BIOCORP, concluded: “This collaboration with AARDEX Group brings a strong added value to our products and to our targeted users. Thanks to the integration with MEMS AS, a unique solution that analyzes deeply patient patterns and behaviors, we will go beyond just monitoring treatment adherence, by providing comprehensive and tailored solutions to boost patient’s engagement and effectively manage this issue. AARDEX specific expertise in clinical trials is also a strong asset and will enable us to create relationships with pharma companies right from the development stage of a drug”.
Medication adherence issues are well known by all healthcare stakeholders and its clinical and commercial impact have been quantified and heavily documented for many years now. The World Health Organization has stated that, in developed countries, adherence to long-term therapies in the general population is only around 50%. But this issue is not limited to commercialized drugs and real-life conditions, it also massively affects clinical trials, which impacts assessment of drug efficacy.
ABOUT AARDEX GROUP
AARDEX Group is the world leader in digital solutions to measure and manage medication adherence. Located in Belgium, in Switzerland and in the U.S., AARDEX develops and markets digital solutions for adherence-enhancing strategies in clinical trials, research settings, and professional healthcare systems. AARDEX is the central actor of a complete ecosystem that combines its MEMS® Adherence Software with a wide range of smart packages and devices that measure patient adherence across all routes of drug administration. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment.
For more information, visit www.aardexgroup.com
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005883/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Measuring Muscles with Quantitative MRI: New Study Published in Neurology Expands the Evidence for Using MRI Biomarkers in SBMA26.8.2026 14:27:00 CEST | Press release
AMRA Medical is pleased to announce the publication of new research in Neurology demonstrating the potential of quantitative whole-body MRI to measure disease progression in Spinal and Bulbar Muscular Atrophy (SBMA), a rare, progressive neuromuscular disease. The research was also selected for the cover of the issue, providing additional visibility for this important work in neuromuscular disease research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826386576/en/ AMRA Medical - Measuring Muscles with Quantitative MRI The manuscript, titled “Muscle MRI as an imaging biomarker of muscle damage in patients with spinal and bulbar muscular atrophy” highlights how MRI-based muscle composition biomarkers can provide sensitive and objective measures of disease-related change over time. With AMRAⓇ Researcher, the study evaluated 25 participants with SBMA to investigate the ability of fat-referenced MRI to assess changes in musc
KEWPIE IT. London discovers the Mayo behind the Iconic Tamago Sando26.8.2026 14:10:00 CEST | Press release
KEWPIE MAYONNAISE launches new campaign celebrating the simple ingredient that transforms an everyday Egg Sandwich into something memorable. What makes the Tamago Sando so extraordinary? The answer is simple: KEWPIE IT. Covent Garden Piazza, London, 19-20 September 2026 Kewpie Corporation(TOKYO:2809) is inviting Londoners to discover how one simple squeeze can transform one of the world's most iconic sandwiches. Through a new experiential pop-up in Covent Garden Piazza, the iconic Japanese mayonnaise brand is bringing its rich, creamy, umami flavour to the heart of London's food scene, celebrating the ingredient that elevates the Tamago Sando AKAthe iconic Japanese Egg Sandwich. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826081552/en/ An image of the pop-up scheduled to take place at Covent Garden Piazza in London KEWPIE MAYONNAISE is mostly made with egg yolks (not whole eggs), which is responsible for its richness a
NetApp Named a Leader in the 2026 Gartner® Magic Quadrant™ for Enterprise Storage Platforms26.8.2026 14:00:00 CEST | Press release
NetApp is ranked first in the Hybrid Cloud Storage Use Case in the 2026 Gartner® Critical Capabilities for Enterprise Storage Platforms NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced it has been recognized by Gartner as a Leader in the 2026 Gartner Magic Quadrant for Enterprise Storage Platforms, continuing to acknowledge NetApp as a Leader in this market from its inaugural edition of this report in 2025. The evaluation was based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute. Additionally, the 2026 Gartner Critical Capabilities for Enterprise Storage Platforms report ranks NetApp first in the Hybrid Cloud Storage Use Case and second in the Hybrid Platform Services Use Case. NetApp believes this recognition validates the company’s ability to help customers address their most pressing data challenges while offering more predictable hardware delivery timelines than its competitors. The NetApp Pl
Copeland Appoints Sandro Matic as President, Americas, and Gwen Cheramy as President, Europe26.8.2026 14:00:00 CEST | Press release
Leadership appointments support continuity and execution across Copeland's global operations Copeland, a global provider of compression technologies and controls solutions, today announced that Gwen Cheramy will join the company as President of its Europe business on Oct. 1, 2026, and that Sandro Matic will assume the role of President of its Americas business on Sept. 1, 2026. Matic will continue to lead Europe on an interim basis until Cheramy joins Copeland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826567313/en/ Sandro Matic, President, Americas for Copeland "Sandro and Gwen are both proven leaders with strong track records of delivering results within our industry,” said Ross B. Shuster, CEO of Copeland. "In their new roles, they will be instrumental in providing leadership to our local colleagues, supporting our customers, and advancing Copeland’s strategic priorities across their respective regions while helpi
Pure Lithium Announces Unprecedented Cycling Results From ItsAdvanced Anode™ Lithium Metal Battery Technology26.8.2026 13:00:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, today announced that our Advanced Anode™ battery, technology developed specifically to enable ultra-long cycling, has achieved more than 9,315 cycles. The cells continue to cycle in the Company's laboratory. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826201214/en/ To the Company’s knowledge, no other lithium metal battery in development has achieved such results under equivalent testing conditions. The performance of the Company’s battery, achieved with negligible capacity fade, far exceeds today’s commercial lithium-ion battery cycling requirements across numerous applications, where performance typically ranges from 250 to 2,000 cycles, depending on the application. These results were achieved at 100% depth of discharge, and charge rates of 1C: 1C.1 “The results of Pure Lithium’s cycling performance are disruptive. Cycle life
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom